Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2029
The next-generation sequencing market is expected to reach USD 22.38 billion in 2029 from USD 13.28 billion in 2024, at a CAGR of 11.0% during the forecast period.
The increasing adoption of NGS in areas like oncology, infectious diseases, reproductive health, metagenomics, and personalized medicine is a major growth driver. Moreover, improved bioinformatics tools for data analysis and interpretation are enhancing the usability of NGS, driving its widespread adoption.
“The consumables segment accounted for the largest share by products segment in the NGS market in 2023”
The NGS products market is divided into consumables, platforms, and bioinformatics tools. The consumables holds the largest share of the market in 2023. The consumables is the segment with the largest share in products. The consumables segment dominates the product type category of the NGS market. These include reagents, library preparation kits, sequencing flow cells, and sample preparation kits, which are consumed in large volumes across diverse applications. The ongoing need for high-quality consumables ensures a steady demand, unlike instruments that represent one-time purchases. Additionally, the increasing adoption of targeted sequencing and custom panels drives the demand for specialized consumables tailored for specific research and clinical applications. The growing number of NGS users, coupled with advancements in sequencing chemistries, has further increased the reliance on consumables to optimize workflows and improve data quality.
“The academic & research institutes segment accounted for the largest share by services end-user segment in the NGS market in 2023”
The NGS services market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, and other end users. The academic & research institutes are the segment with the largest share in the end-user segment in 2023. The large share of academic & research institutes is due to these institutions benefit from substantial government and private funding for research projects, enabling significant investments in NGS products, including instruments and consumables. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment.
“The Asia Pacific region is growing at the highest CAGR in the NGS market from 2024 to 2029.”
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the rising demand for precision medicines is supporting the growth. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of sequencing technologies in healthcare management and treatment driving the market growth.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the NGS market by offerings (products and services), products by type (consumables, platforms, bioinformatics tools), consumables (library preparation kits & reagents, sequencing kits & reagents, and other consumables), platforms (sequencing platforms, library preparation platforms), bioinformatics tools (data analysis software & workbenches, data visualization tools, and other tools), platforms by technology (sequencing by synthesis, ion semiconductor sequencing, single-molecule real time sequencing, nanopore sequencing, and other sequencing technologies), products by workflow (presequencing, sequencing , and data analysis), products by end user (academic and research institutes, pharmaceutical and biotechnology companies, clinical & diagnostics laboratories, and other end users), services by type (sequencing services, presequencing services, bioinformatics and data analysis services, and services for NGS platforms), presequencing services by type (library preparation & target enrichment, sample preparation, and quality control), sequencing services by type (exome & targeted resequencing and custom panels, rna sequencing, de novo sequencing, chip sequencing, whole genome sequencing, methyl sequencing, and other sequencing services), bioinformatics & data analysis services by type (data analysis services, data visualization and interpretation, data storage and management services), services by workflow (presequencing services, sequencing services, and data analysis services), servuces by end user (academics and research institutes, pharmaceutical and biotechnology companies, hospitals and clinical laboratories, other end users), application (drug discovery & development, diagnostics, agriculture and animal research, and other applications), diagnostic applications (cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics, and other diagnostic applications), drug discovery & development application (pharmacogenomics, and other drug discovery & development applications), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the NGS market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the NGS market. Competitive analysis of top players and upcoming startups in the NGS market ecosystem is covered in this report
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall NGS market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Advancements in sequencing platforms, Rising clinical applications of sequencing, Growing demand for precision medicine, Declining sequencing cost), restraints (Data analysis complexity, High initial capital investment), opportunities (Integration of AI and ML, adoption of long-read sequencing technologies, emphasis on multiomics integration), and challenges (Standardization issues) influencing the growth of the market.
The increasing adoption of NGS in areas like oncology, infectious diseases, reproductive health, metagenomics, and personalized medicine is a major growth driver. Moreover, improved bioinformatics tools for data analysis and interpretation are enhancing the usability of NGS, driving its widespread adoption.
“The consumables segment accounted for the largest share by products segment in the NGS market in 2023”
The NGS products market is divided into consumables, platforms, and bioinformatics tools. The consumables holds the largest share of the market in 2023. The consumables is the segment with the largest share in products. The consumables segment dominates the product type category of the NGS market. These include reagents, library preparation kits, sequencing flow cells, and sample preparation kits, which are consumed in large volumes across diverse applications. The ongoing need for high-quality consumables ensures a steady demand, unlike instruments that represent one-time purchases. Additionally, the increasing adoption of targeted sequencing and custom panels drives the demand for specialized consumables tailored for specific research and clinical applications. The growing number of NGS users, coupled with advancements in sequencing chemistries, has further increased the reliance on consumables to optimize workflows and improve data quality.
“The academic & research institutes segment accounted for the largest share by services end-user segment in the NGS market in 2023”
The NGS services market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, and other end users. The academic & research institutes are the segment with the largest share in the end-user segment in 2023. The large share of academic & research institutes is due to these institutions benefit from substantial government and private funding for research projects, enabling significant investments in NGS products, including instruments and consumables. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment.
“The Asia Pacific region is growing at the highest CAGR in the NGS market from 2024 to 2029.”
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the rising demand for precision medicines is supporting the growth. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of sequencing technologies in healthcare management and treatment driving the market growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.
- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Danaher Corporation (US)
- QIAGEN (Netherlands)
- Agilent Technologies, Inc. (US)
- Revvity (US)
- Eurofins Scientific (Luxembourg)
- PacBio (US)
- Oxford Nanopore Technologies plc. (UK)
- Takara Bio Inc. (Japan)
- BGI Group (China)
- Merck KGaA (Germany)
- BD (US)
- 10X Genomics (US)
- New England Biolabs (US)
- Promega Corporation (US)
- Novogene Co., Ltd. (China)
- LGC Limited (UK)
- WuXi Biologics (China)
- MGI Tech Co. Ltd. (China)
- Tecan Trading AG (Switzerland)
- Twist Biosciences (US)
- Azenta US, Inc. (US)
- GenScript (US)
- SD Biosensor, Inc. (South Korea)
- Fulgent Genetics (US)
- Hamilton Company (US)
- Zymo Research Corporation (US)
- NeoGenomics Laboratories (US)
- Psomagen (US)
This research report categorizes the NGS market by offerings (products and services), products by type (consumables, platforms, bioinformatics tools), consumables (library preparation kits & reagents, sequencing kits & reagents, and other consumables), platforms (sequencing platforms, library preparation platforms), bioinformatics tools (data analysis software & workbenches, data visualization tools, and other tools), platforms by technology (sequencing by synthesis, ion semiconductor sequencing, single-molecule real time sequencing, nanopore sequencing, and other sequencing technologies), products by workflow (presequencing, sequencing , and data analysis), products by end user (academic and research institutes, pharmaceutical and biotechnology companies, clinical & diagnostics laboratories, and other end users), services by type (sequencing services, presequencing services, bioinformatics and data analysis services, and services for NGS platforms), presequencing services by type (library preparation & target enrichment, sample preparation, and quality control), sequencing services by type (exome & targeted resequencing and custom panels, rna sequencing, de novo sequencing, chip sequencing, whole genome sequencing, methyl sequencing, and other sequencing services), bioinformatics & data analysis services by type (data analysis services, data visualization and interpretation, data storage and management services), services by workflow (presequencing services, sequencing services, and data analysis services), servuces by end user (academics and research institutes, pharmaceutical and biotechnology companies, hospitals and clinical laboratories, other end users), application (drug discovery & development, diagnostics, agriculture and animal research, and other applications), diagnostic applications (cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics, and other diagnostic applications), drug discovery & development application (pharmacogenomics, and other drug discovery & development applications), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the NGS market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the NGS market. Competitive analysis of top players and upcoming startups in the NGS market ecosystem is covered in this report
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall NGS market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Advancements in sequencing platforms, Rising clinical applications of sequencing, Growing demand for precision medicine, Declining sequencing cost), restraints (Data analysis complexity, High initial capital investment), opportunities (Integration of AI and ML, adoption of long-read sequencing technologies, emphasis on multiomics integration), and challenges (Standardization issues) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products/services of the NGS market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the genomics market
- Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd. (China), Tecan Trading AG (Switzerland), Twist Biosciences (US), Azenta US, Inc. (US), GenScript (US), SD Biosensor, Inc. (South Korea), Fulgent Genetics (US), Hamilton Company (US), Zymo Research Corporation (US), NeoGenomics Laboratories (US), and Psomagen (US).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NGS MARKET OVERVIEW
4.2 ASIA PACIFIC: NGS MARKET, BY COUNTRY AND PRODUCT TYPE
4.3 NGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 NGS PRODUCTS MARKET SHARE, BY END USER, 2023
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in sequencing platforms
5.2.1.1.1 Revio
5.2.1.1.2 PromethION 2 Solo
5.2.1.1.3 Ion Torrent Genexus Dx
5.2.1.2 Rising clinical applications of sequencing
5.2.1.3 Growing demand for precision medicine
5.2.1.4 Declining costs of sequencing
5.2.2 RESTRAINTS
5.2.2.1 Data analysis complexity
5.2.2.2 High capital investment and expenses
5.2.3 OPPORTUNITIES
5.2.3.1 Integration of AI and ML
5.2.3.2 Adoption of long-read sequencing technologies
5.2.3.3 Emphasis on multiomics integration
5.2.4 CHALLENGES
5.2.4.1 Standardization issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 REGULATORY LANDSCAPE
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4.2 REGULATORY FRAMEWORK
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Sequencing by synthesis
5.6.1.2 Single-molecule real-time sequencing
5.6.1.3 Nanopore sequencing
5.6.1.4 Ion semiconductor sequencing
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Automated sample preparation systems
5.6.2.2 Bioinformatics and data analysis platforms
5.6.2.3 CRISPR-based targeted sequencing
5.6.2.4 Multiplex PCR
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Single-cell sequencing technology
5.6.3.2 Multi-omics integration
5.6.3.3 Spatial genomics and transcriptomics
5.6.3.4 Gene editing technologies
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.7.1.1 Average selling price trend of instruments, by key player,
2018–2023
5.7.1.2 Average selling price trend of consumables, by key player,
2022–2024
5.7.1.3 Average selling price of services, by key player, 2024
5.7.2 AVERAGE SELLING PRICE, BY REGION
5.8 PATENT ANALYSIS
5.9 SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2024–2025
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 KEY BUYING CRITERIA, BY END USER
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 CASE STUDY ANALYSIS
5.15.1 CASE STUDY 1: IDENTIFYING TANDEM REPEAT LINKED TO ALS USING SMRT SEQUENCING
5.15.2 CASE STUDY 2: LONG-READ WHOLE-GENOME SEQUENCING AT CHILDREN’S MERCY KANSAS CITY
5.15.3 CASE STUDY 3: SNP ARRAY IDENTIFIED INHERITED GENETIC DISORDER CONTRIBUTING TO IVF FAILURES
5.16 TRADE ANALYSIS
5.16.1 IMPORT DATA
5.16.2 EXPORT DATA
5.17 IMPACT OF AI ON NEXT-GENERATION SEQUENCING MARKET
6 NEXT-GENERATION SEQUENCING MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 WIDE DEMAND FOR CONSUMABLES AND TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
6.3 SERVICES
6.3.1 SHIFT TOWARD SERVICE-BASED MODELS TO DRIVE MARKET
7 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 LIBRARY PREPARATION & AND REAGENTS
7.2.1.1 Strong demand and growing applications to ensure market growth
7.2.2 SEQUENCING KITS & REAGENTS
7.2.2.1 Technological advancements to support market growth
7.2.3 OTHER CONSUMABLES
7.3 PLATFORMS
7.3.1 SEQUENCING PLATFORMS
7.3.1.1 Illumina
7.3.1.1.1 NovaSeq
7.3.1.1.1.1 Flexibility and automated data processing to reduce time and labor cost
7.3.1.1.2 NextSeq
7.3.1.1.2.1 Introduction of advanced systems to affect demand for NextSeq
7.3.1.1.3 MiSeq
7.3.1.1.3.1 Small size and rapid operations to drive adoption in clinical labs
7.3.1.1.4 MiniSeq
7.3.1.1.4.1 Cross-application flexibility and small footprint to propel demand
7.3.1.1.5 iSeq 100
7.3.1.1.5.1 High accuracy and lower costs to support market growth
7.3.1.2 Thermo Fisher Scientific
7.3.1.3 PacBio
7.3.1.4 Oxford Nanopore Technologies
7.3.1.5 Other sequencing platforms
7.3.2 LIBRARY PREPARATION PLATFORMS
7.3.2.1 Rising demand for sequencing in clinical applications to drive market
7.4 BIOINFORMATICS TOOLS
7.4.1 DATA ANALYSIS SOFTWARE & WORKBENCHES
7.4.1.1 Demand for genome analysis in clinical diagnostics to support market growth
7.4.2 DATA VISUALIZATION TOOLS
7.4.2.1 Rising demand for sequencing-based research to support market growth
7.4.3 OTHER BIOINFORMATICS TOOLS
8 NEXT-GENERATION SEQUENCING PLATFORMS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 SEQUENCING BY SYNTHESIS
8.2.1 HIGH, RAPID PRODUCTION OF BASE PAIRS TO SUPPORT ADOPTION
8.3 ION SEMICONDUCTOR SEQUENCING
8.3.1 SIMPLER WORKFLOW AND COST-EFFECTIVENESS TO SUPPORT MARKET GROWTH
8.4 SMRT SEQUENCING
8.4.1 RAPID RESULTS AND LOWER SEQUENCING COSTS TO DRIVE MARKET
8.5 NANOPORE SEQUENCING
8.5.1 DIRECT RNA SEQUENCING CAPABILITIES TO PROPEL DEMAND
8.6 OTHER SEQUENCING TECHNOLOGIES
9 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY WORKFLOW
9.1 INTRODUCTION
9.2 SEQUENCING
9.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET
9.3 PRESEQUENCING
9.3.1 DEVELOPMENT OF ADVANCED LIBRARY PREPARATION SOLUTIONS TO BOOST MARKET GROWTH
9.4 DATA ANALYSIS
9.4.1 DEVELOPMENT OF ADVANCED BIOINFORMATICS SOLUTIONS TO DRIVE MARKET
10 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 RISING RESEARCH INTENSITY FOR GENOME RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 RISING DEMAND FOR COMPREHENSIVE SEQUENCING DATA IN GENETIC RESEARCH TO DRIVE MARKET
10.4 CLINICAL & DIAGNOSTIC LABORATORIES
10.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
10.5 OTHER END USERS
11 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE
11.1 INTRODUCTION
11.2 SEQUENCING SERVICES
11.2.1 EXOME & TARGETED RESEQUENCING AND CUSTOM PANELS
11.2.1.1 Development of technologically advanced NGS products and services to propel growth
11.2.2 RNA SEQUENCING
11.2.2.1 Technological advancements to support market growth
11.2.3 DE NOVO SEQUENCING
11.2.3.1 Rising awareness of De Novo sequencing to drive market
11.2.4 CHIP SEQUENCING
11.2.4.1 Increased demand for ChIP sequencing to propel growth
11.2.5 WHOLE-GENOME SEQUENCING
11.2.5.1 Reduced cost of WGS to support market growth
11.2.6 METHYL SEQUENCING
11.2.6.1 Increased demand for methyl sequencing in cancer research to support market growth
11.2.7 OTHER SEQUENCING SERVICES
11.3 PRESEQUENCING SERVICES
11.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
11.3.1.1 Development of advanced library preparation solutions to drive market
11.3.2 SAMPLE PREPARATION
11.3.2.1 Development of automated sample preparation solutions to boost growth
11.3.3 QUALITY CONTROL
11.3.3.1 Importance of quality control in NGS workflow to boost growth
11.4 BIOINFORMATICS & DATA ANALYSIS SERVICES
11.4.1 DATA ANALYSIS
11.4.1.1 Increasing demand for genome analysis for clinical diagnosis to drive market
11.4.2 DATA VISUALIZATION & INTERPRETATION
11.4.2.1 Rising demand for sequencing-based research to support market growth
11.4.3 DATA STORAGE & MANAGEMENT
11.4.3.1 Demand for effective data management to propel market growth
11.5 NGS PLATFORM SERVICES
11.5.1 NEED FOR COMPLIANCE AND MINIMIZING PLATFORM DOWNTIME TO DRIVE ADOPTION
12 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW
12.1 INTRODUCTION
12.2 SEQUENCING
12.2.1 RISING DEMAND FOR SEQUENCING SERVICES AND APPLICATIONS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
12.3 PRESEQUENCING SERVICES
12.3.1 CUSTOM DEVELOPMENT OF SAMPLES FOR SEQUENCING TO BOOST MARKET GROWTH
12.4 DATA ANALYSIS SERVICES
12.4.1 RISING DEMAND FOR ADVANCED RESEARCH TO DRIVE MARKET
13 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER
13.1 INTRODUCTION
13.2 ACADEMIC & RESEARCH INSTITUTES
13.2.1 RISING RESEARCH INTENSITY TO SUPPORT MARKET GROWTH
13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.3.1 RISING DEMAND FOR COMPREHENSIVE GENETIC DATA TO DRIVE GROWTH
13.4 HOSPITALS & CLINICAL LABORATORIES
13.4.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
13.5 OTHER END USERS
14 NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION
14.1 INTRODUCTION
14.2 DIAGNOSTICS
14.2.1 CANCER DIAGNOSTICS
14.2.1.1 Rising demand for targeted therapies to drive market
14.2.2 INFECTIOUS DISEASE DIAGNOSTICS
14.2.2.1 Rising demand for comprehensive genomic data in clinical diagnostics to propel adoption
14.2.3 REPRODUCTIVE HEALTH DIAGNOSTICS
14.2.3.1 Focus on genetic disease diagnostics to drive growth
14.2.4 OTHER DIAGNOSTIC APPLICATIONS
14.3 DRUG DISCOVERY & DEVELOPMENT
14.3.1 PHARMACOGENOMICS
14.3.1.1 Rising use of NGS for understanding genomic variants in humans to drive growth
14.3.2 OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
14.4 AGRICULTURE & ANIMAL RESEARCH
14.4.1 EMPHASIS ON IMPROVING CROP PRODUCTIVITY TO DRIVE ADOPTION OF NGS
14.5 OTHER APPLICATIONS
15 NEXT-GENERATION SEQUENCING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
15.2.2 US
15.2.2.1 US expected to dominate market in North America
15.2.3 CANADA
15.2.3.1 Increasing government initiatives in sequencing research to boost market growth
15.3 EUROPE
15.3.1 EUROPE: MACROECONOMIC OUTLOOK
15.3.2 GERMANY
15.3.2.1 Germany to dominate European NGS market
15.3.3 UK
15.3.3.1 Strategic initiatives and funding for genomics research to support market growth
15.3.4 FRANCE
15.3.4.1 Increasing government investment in genomics research to drive growth
15.3.5 ITALY
15.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
15.3.6 SPAIN
15.3.6.1 Growing focus on advancements in personalized medicine to support market growth
15.3.7 NETHERLANDS
15.3.7.1 Well-established research infrastructure to sustain demand for NGS
15.3.8 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
15.4.2 CHINA
15.4.2.1 China to dominate Asia Pacific market during forecast period
15.4.3 JAPAN
15.4.3.1 Rising number of collaborations in NGS to drive market
15.4.4 INDIA
15.4.4.1 Government and private initiatives for genomics projects to propel market
15.4.5 AUSTRALIA
15.4.5.1 Increased genetic research in Australia to support market growth
15.4.6 SOUTH KOREA
15.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
15.5.2 BRAZIL
15.5.2.1 Increased government investments in genomics advancements to drive market
15.5.3 MEXICO
15.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
15.6.2 GCC COUNTRIES
15.6.2.1 Saudi Arabia
15.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
15.6.2.2 UAE
15.6.2.2.1 Collaborations to advance genome sequencing and market growth
15.6.2.3 Rest of GCC Countries
15.6.3 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET
15.7.2 AFRICA: MACROECONOMIC OUTLOOK
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NGS MARKET
16.3 REVENUE ANALYSIS, 2019–2023
16.4 MARKET SHARE ANALYSIS, 2023
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Application footprint
16.5.5.5 Technology footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of startups/SMEs
16.7 VALUATION & FINANCIAL METRICS
16.7.1 FINANCIAL METRICS
16.7.2 COMPANY VALUATION
16.8 BRAND/PRODUCT COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 DEALS
16.9.2 EXPANSIONS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 ILLUMINA, INC.
17.1.1.1 Business overview
17.1.1.2 Products/services offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses and competitive threats
17.1.2 THERMO FISHER SCIENTIFIC INC.
17.1.2.1 Business overview
17.1.2.2 Products/services offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches, approvals, and enhancements
17.1.2.3.2 Deals
17.1.2.3.3 Expansions
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses and competitive threats
17.1.3 AGILENT TECHNOLOGIES, INC.
17.1.3.1 Business overview
17.1.3.2 Products/services offered
17.1.3.3 Recent developments
17.1.3.3.1 Deals
17.1.3.3.2 Expansions
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses and competitive threats
17.1.4 F. HOFFMANN-LA ROCHE LTD.
17.1.4.1 Business overview
17.1.4.2 Products/services offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.3.2 Deals
17.1.5 DANAHER CORPORATION
17.1.5.1 Business overview
17.1.5.2 Products/services offered
17.1.5.3 Recent developments
17.1.5.3.1 Product launches & approvals
17.1.5.3.2 Deals
17.1.5.3.3 Expansions
17.1.6 QIAGEN
17.1.6.1 Business overview
17.1.6.2 Products/services offered
17.1.6.3 Recent developments
17.1.6.3.1 Deals
17.1.6.3.2 Expansions
17.1.7 REVVITY
17.1.7.1 Business overview
17.1.7.2 Products/services offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches
17.1.7.3.2 Deals
17.1.7.3.3 Expansions
17.1.8 EUROFINS SCIENTIFIC
17.1.8.1 Business overview
17.1.8.2 Products/services offered
17.1.8.3 Recent developments
17.1.8.3.1 Service launches
17.1.8.3.2 Deals
17.1.9 PACBIO
17.1.9.1 Business overview
17.1.9.2 Products/services offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches
17.1.9.3.2 Deals
17.1.9.3.3 Expansions
17.1.9.3.4 Other developments
17.1.10 OXFORD NANOPORE TECHNOLOGIES PLC.
17.1.10.1 Business overview
17.1.10.2 Products/services offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches
17.1.10.3.2 Deals
17.1.11 TAKARA BIO INC.
17.1.11.1 Business overview
17.1.11.2 Products/services offered
17.1.11.3 Recent developments
17.1.11.3.1 Product launches
17.1.11.3.2 Deals
17.1.12 BGI GROUP
17.1.12.1 Business overview
17.1.12.2 Products/services offered
17.1.12.3 Recent developments
17.1.12.3.1 Product & service launches and approvals
17.1.12.3.2 Deals
17.1.12.3.3 Other developments
17.1.13 BD
17.1.13.1 Business overview
17.1.13.2 Products/services offered
17.1.13.3 Recent developments
17.1.13.3.1 Product & service launches
17.1.13.3.2 Deals
17.1.14 10X GENOMICS
17.1.14.1 Business overview
17.1.14.2 Products/services offered
17.1.14.3 Recent developments
17.1.14.3.1 Product launches
17.1.15 PROMEGA CORPORATION
17.1.15.1 Business overview
17.1.15.2 Products/services offered
17.1.15.3 Recent developments
17.1.15.3.1 Expansions
17.1.16 LGC LIMITED
17.1.16.1 Business overview
17.1.16.2 Products/services offered
17.1.16.2.1 Deals
17.1.17 WUXI BIOLOGICS
17.1.17.1 Business overview
17.1.17.2 Products/services offered
17.1.18 TECAN TRADING AG
17.1.18.1 Business overview
17.1.18.2 Products/services offered
17.1.18.2.1 Deals
17.1.19 TWIST BIOSCIENCES
17.1.19.1 Business overview
17.1.19.2 Products/services offered
17.1.19.3 Recent developments
17.1.19.3.1 Product launches
17.1.19.3.2 Deals
17.1.20 AZENTA US, INC.
17.1.20.1 Business overview
17.1.20.2 Products & services offered
17.1.20.3 Recent developments
17.1.20.3.1 Deals
17.2 OTHER PLAYERS
17.2.1 MGI TECH CO. LTD.
17.2.2 NOVOGENE CO., LTD.
17.2.3 NEW ENGLAND BIOLABS
17.2.4 GENSCRIPT
17.2.5 PSOMAGEN
17.2.6 ZYMO RESEARCH CORPORATION
17.2.7 HAMILTON COMPANY
17.2.8 NEOGENOMICS LABORATORIES
17.2.9 FULGENT GENETICS
17.2.10 SD BIOSENSOR, INC.
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NGS MARKET OVERVIEW
4.2 ASIA PACIFIC: NGS MARKET, BY COUNTRY AND PRODUCT TYPE
4.3 NGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 NGS PRODUCTS MARKET SHARE, BY END USER, 2023
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in sequencing platforms
5.2.1.1.1 Revio
5.2.1.1.2 PromethION 2 Solo
5.2.1.1.3 Ion Torrent Genexus Dx
5.2.1.2 Rising clinical applications of sequencing
5.2.1.3 Growing demand for precision medicine
5.2.1.4 Declining costs of sequencing
5.2.2 RESTRAINTS
5.2.2.1 Data analysis complexity
5.2.2.2 High capital investment and expenses
5.2.3 OPPORTUNITIES
5.2.3.1 Integration of AI and ML
5.2.3.2 Adoption of long-read sequencing technologies
5.2.3.3 Emphasis on multiomics integration
5.2.4 CHALLENGES
5.2.4.1 Standardization issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 REGULATORY LANDSCAPE
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4.2 REGULATORY FRAMEWORK
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Sequencing by synthesis
5.6.1.2 Single-molecule real-time sequencing
5.6.1.3 Nanopore sequencing
5.6.1.4 Ion semiconductor sequencing
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Automated sample preparation systems
5.6.2.2 Bioinformatics and data analysis platforms
5.6.2.3 CRISPR-based targeted sequencing
5.6.2.4 Multiplex PCR
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Single-cell sequencing technology
5.6.3.2 Multi-omics integration
5.6.3.3 Spatial genomics and transcriptomics
5.6.3.4 Gene editing technologies
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.7.1.1 Average selling price trend of instruments, by key player,
2018–2023
5.7.1.2 Average selling price trend of consumables, by key player,
2022–2024
5.7.1.3 Average selling price of services, by key player, 2024
5.7.2 AVERAGE SELLING PRICE, BY REGION
5.8 PATENT ANALYSIS
5.9 SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2024–2025
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 INTENSITY OF COMPETITIVE RIVALRY
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 KEY BUYING CRITERIA, BY END USER
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 CASE STUDY ANALYSIS
5.15.1 CASE STUDY 1: IDENTIFYING TANDEM REPEAT LINKED TO ALS USING SMRT SEQUENCING
5.15.2 CASE STUDY 2: LONG-READ WHOLE-GENOME SEQUENCING AT CHILDREN’S MERCY KANSAS CITY
5.15.3 CASE STUDY 3: SNP ARRAY IDENTIFIED INHERITED GENETIC DISORDER CONTRIBUTING TO IVF FAILURES
5.16 TRADE ANALYSIS
5.16.1 IMPORT DATA
5.16.2 EXPORT DATA
5.17 IMPACT OF AI ON NEXT-GENERATION SEQUENCING MARKET
6 NEXT-GENERATION SEQUENCING MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 WIDE DEMAND FOR CONSUMABLES AND TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
6.3 SERVICES
6.3.1 SHIFT TOWARD SERVICE-BASED MODELS TO DRIVE MARKET
7 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 LIBRARY PREPARATION & AND REAGENTS
7.2.1.1 Strong demand and growing applications to ensure market growth
7.2.2 SEQUENCING KITS & REAGENTS
7.2.2.1 Technological advancements to support market growth
7.2.3 OTHER CONSUMABLES
7.3 PLATFORMS
7.3.1 SEQUENCING PLATFORMS
7.3.1.1 Illumina
7.3.1.1.1 NovaSeq
7.3.1.1.1.1 Flexibility and automated data processing to reduce time and labor cost
7.3.1.1.2 NextSeq
7.3.1.1.2.1 Introduction of advanced systems to affect demand for NextSeq
7.3.1.1.3 MiSeq
7.3.1.1.3.1 Small size and rapid operations to drive adoption in clinical labs
7.3.1.1.4 MiniSeq
7.3.1.1.4.1 Cross-application flexibility and small footprint to propel demand
7.3.1.1.5 iSeq 100
7.3.1.1.5.1 High accuracy and lower costs to support market growth
7.3.1.2 Thermo Fisher Scientific
7.3.1.3 PacBio
7.3.1.4 Oxford Nanopore Technologies
7.3.1.5 Other sequencing platforms
7.3.2 LIBRARY PREPARATION PLATFORMS
7.3.2.1 Rising demand for sequencing in clinical applications to drive market
7.4 BIOINFORMATICS TOOLS
7.4.1 DATA ANALYSIS SOFTWARE & WORKBENCHES
7.4.1.1 Demand for genome analysis in clinical diagnostics to support market growth
7.4.2 DATA VISUALIZATION TOOLS
7.4.2.1 Rising demand for sequencing-based research to support market growth
7.4.3 OTHER BIOINFORMATICS TOOLS
8 NEXT-GENERATION SEQUENCING PLATFORMS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 SEQUENCING BY SYNTHESIS
8.2.1 HIGH, RAPID PRODUCTION OF BASE PAIRS TO SUPPORT ADOPTION
8.3 ION SEMICONDUCTOR SEQUENCING
8.3.1 SIMPLER WORKFLOW AND COST-EFFECTIVENESS TO SUPPORT MARKET GROWTH
8.4 SMRT SEQUENCING
8.4.1 RAPID RESULTS AND LOWER SEQUENCING COSTS TO DRIVE MARKET
8.5 NANOPORE SEQUENCING
8.5.1 DIRECT RNA SEQUENCING CAPABILITIES TO PROPEL DEMAND
8.6 OTHER SEQUENCING TECHNOLOGIES
9 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY WORKFLOW
9.1 INTRODUCTION
9.2 SEQUENCING
9.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET
9.3 PRESEQUENCING
9.3.1 DEVELOPMENT OF ADVANCED LIBRARY PREPARATION SOLUTIONS TO BOOST MARKET GROWTH
9.4 DATA ANALYSIS
9.4.1 DEVELOPMENT OF ADVANCED BIOINFORMATICS SOLUTIONS TO DRIVE MARKET
10 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 RISING RESEARCH INTENSITY FOR GENOME RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 RISING DEMAND FOR COMPREHENSIVE SEQUENCING DATA IN GENETIC RESEARCH TO DRIVE MARKET
10.4 CLINICAL & DIAGNOSTIC LABORATORIES
10.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
10.5 OTHER END USERS
11 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE
11.1 INTRODUCTION
11.2 SEQUENCING SERVICES
11.2.1 EXOME & TARGETED RESEQUENCING AND CUSTOM PANELS
11.2.1.1 Development of technologically advanced NGS products and services to propel growth
11.2.2 RNA SEQUENCING
11.2.2.1 Technological advancements to support market growth
11.2.3 DE NOVO SEQUENCING
11.2.3.1 Rising awareness of De Novo sequencing to drive market
11.2.4 CHIP SEQUENCING
11.2.4.1 Increased demand for ChIP sequencing to propel growth
11.2.5 WHOLE-GENOME SEQUENCING
11.2.5.1 Reduced cost of WGS to support market growth
11.2.6 METHYL SEQUENCING
11.2.6.1 Increased demand for methyl sequencing in cancer research to support market growth
11.2.7 OTHER SEQUENCING SERVICES
11.3 PRESEQUENCING SERVICES
11.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
11.3.1.1 Development of advanced library preparation solutions to drive market
11.3.2 SAMPLE PREPARATION
11.3.2.1 Development of automated sample preparation solutions to boost growth
11.3.3 QUALITY CONTROL
11.3.3.1 Importance of quality control in NGS workflow to boost growth
11.4 BIOINFORMATICS & DATA ANALYSIS SERVICES
11.4.1 DATA ANALYSIS
11.4.1.1 Increasing demand for genome analysis for clinical diagnosis to drive market
11.4.2 DATA VISUALIZATION & INTERPRETATION
11.4.2.1 Rising demand for sequencing-based research to support market growth
11.4.3 DATA STORAGE & MANAGEMENT
11.4.3.1 Demand for effective data management to propel market growth
11.5 NGS PLATFORM SERVICES
11.5.1 NEED FOR COMPLIANCE AND MINIMIZING PLATFORM DOWNTIME TO DRIVE ADOPTION
12 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW
12.1 INTRODUCTION
12.2 SEQUENCING
12.2.1 RISING DEMAND FOR SEQUENCING SERVICES AND APPLICATIONS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
12.3 PRESEQUENCING SERVICES
12.3.1 CUSTOM DEVELOPMENT OF SAMPLES FOR SEQUENCING TO BOOST MARKET GROWTH
12.4 DATA ANALYSIS SERVICES
12.4.1 RISING DEMAND FOR ADVANCED RESEARCH TO DRIVE MARKET
13 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER
13.1 INTRODUCTION
13.2 ACADEMIC & RESEARCH INSTITUTES
13.2.1 RISING RESEARCH INTENSITY TO SUPPORT MARKET GROWTH
13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.3.1 RISING DEMAND FOR COMPREHENSIVE GENETIC DATA TO DRIVE GROWTH
13.4 HOSPITALS & CLINICAL LABORATORIES
13.4.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
13.5 OTHER END USERS
14 NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION
14.1 INTRODUCTION
14.2 DIAGNOSTICS
14.2.1 CANCER DIAGNOSTICS
14.2.1.1 Rising demand for targeted therapies to drive market
14.2.2 INFECTIOUS DISEASE DIAGNOSTICS
14.2.2.1 Rising demand for comprehensive genomic data in clinical diagnostics to propel adoption
14.2.3 REPRODUCTIVE HEALTH DIAGNOSTICS
14.2.3.1 Focus on genetic disease diagnostics to drive growth
14.2.4 OTHER DIAGNOSTIC APPLICATIONS
14.3 DRUG DISCOVERY & DEVELOPMENT
14.3.1 PHARMACOGENOMICS
14.3.1.1 Rising use of NGS for understanding genomic variants in humans to drive growth
14.3.2 OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
14.4 AGRICULTURE & ANIMAL RESEARCH
14.4.1 EMPHASIS ON IMPROVING CROP PRODUCTIVITY TO DRIVE ADOPTION OF NGS
14.5 OTHER APPLICATIONS
15 NEXT-GENERATION SEQUENCING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
15.2.2 US
15.2.2.1 US expected to dominate market in North America
15.2.3 CANADA
15.2.3.1 Increasing government initiatives in sequencing research to boost market growth
15.3 EUROPE
15.3.1 EUROPE: MACROECONOMIC OUTLOOK
15.3.2 GERMANY
15.3.2.1 Germany to dominate European NGS market
15.3.3 UK
15.3.3.1 Strategic initiatives and funding for genomics research to support market growth
15.3.4 FRANCE
15.3.4.1 Increasing government investment in genomics research to drive growth
15.3.5 ITALY
15.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
15.3.6 SPAIN
15.3.6.1 Growing focus on advancements in personalized medicine to support market growth
15.3.7 NETHERLANDS
15.3.7.1 Well-established research infrastructure to sustain demand for NGS
15.3.8 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
15.4.2 CHINA
15.4.2.1 China to dominate Asia Pacific market during forecast period
15.4.3 JAPAN
15.4.3.1 Rising number of collaborations in NGS to drive market
15.4.4 INDIA
15.4.4.1 Government and private initiatives for genomics projects to propel market
15.4.5 AUSTRALIA
15.4.5.1 Increased genetic research in Australia to support market growth
15.4.6 SOUTH KOREA
15.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
15.5.2 BRAZIL
15.5.2.1 Increased government investments in genomics advancements to drive market
15.5.3 MEXICO
15.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico
15.5.4 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
15.6.2 GCC COUNTRIES
15.6.2.1 Saudi Arabia
15.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
15.6.2.2 UAE
15.6.2.2.1 Collaborations to advance genome sequencing and market growth
15.6.2.3 Rest of GCC Countries
15.6.3 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET
15.7.2 AFRICA: MACROECONOMIC OUTLOOK
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NGS MARKET
16.3 REVENUE ANALYSIS, 2019–2023
16.4 MARKET SHARE ANALYSIS, 2023
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
16.5.1 STARS
16.5.2 EMERGING LEADERS
16.5.3 PERVASIVE PLAYERS
16.5.4 PARTICIPANTS
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
16.5.5.1 Company footprint
16.5.5.2 Region footprint
16.5.5.3 Offering footprint
16.5.5.4 Application footprint
16.5.5.5 Technology footprint
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
16.6.1 PROGRESSIVE COMPANIES
16.6.2 RESPONSIVE COMPANIES
16.6.3 DYNAMIC COMPANIES
16.6.4 STARTING BLOCKS
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
16.6.5.1 Detailed list of key startups/SMEs
16.6.5.2 Competitive benchmarking of startups/SMEs
16.7 VALUATION & FINANCIAL METRICS
16.7.1 FINANCIAL METRICS
16.7.2 COMPANY VALUATION
16.8 BRAND/PRODUCT COMPARISON
16.9 COMPETITIVE SCENARIO
16.9.1 DEALS
16.9.2 EXPANSIONS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 ILLUMINA, INC.
17.1.1.1 Business overview
17.1.1.2 Products/services offered
17.1.1.3 Recent developments
17.1.1.3.1 Product launches
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses and competitive threats
17.1.2 THERMO FISHER SCIENTIFIC INC.
17.1.2.1 Business overview
17.1.2.2 Products/services offered
17.1.2.3 Recent developments
17.1.2.3.1 Product launches, approvals, and enhancements
17.1.2.3.2 Deals
17.1.2.3.3 Expansions
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses and competitive threats
17.1.3 AGILENT TECHNOLOGIES, INC.
17.1.3.1 Business overview
17.1.3.2 Products/services offered
17.1.3.3 Recent developments
17.1.3.3.1 Deals
17.1.3.3.2 Expansions
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses and competitive threats
17.1.4 F. HOFFMANN-LA ROCHE LTD.
17.1.4.1 Business overview
17.1.4.2 Products/services offered
17.1.4.3 Recent developments
17.1.4.3.1 Product launches
17.1.4.3.2 Deals
17.1.5 DANAHER CORPORATION
17.1.5.1 Business overview
17.1.5.2 Products/services offered
17.1.5.3 Recent developments
17.1.5.3.1 Product launches & approvals
17.1.5.3.2 Deals
17.1.5.3.3 Expansions
17.1.6 QIAGEN
17.1.6.1 Business overview
17.1.6.2 Products/services offered
17.1.6.3 Recent developments
17.1.6.3.1 Deals
17.1.6.3.2 Expansions
17.1.7 REVVITY
17.1.7.1 Business overview
17.1.7.2 Products/services offered
17.1.7.3 Recent developments
17.1.7.3.1 Product launches
17.1.7.3.2 Deals
17.1.7.3.3 Expansions
17.1.8 EUROFINS SCIENTIFIC
17.1.8.1 Business overview
17.1.8.2 Products/services offered
17.1.8.3 Recent developments
17.1.8.3.1 Service launches
17.1.8.3.2 Deals
17.1.9 PACBIO
17.1.9.1 Business overview
17.1.9.2 Products/services offered
17.1.9.3 Recent developments
17.1.9.3.1 Product launches
17.1.9.3.2 Deals
17.1.9.3.3 Expansions
17.1.9.3.4 Other developments
17.1.10 OXFORD NANOPORE TECHNOLOGIES PLC.
17.1.10.1 Business overview
17.1.10.2 Products/services offered
17.1.10.3 Recent developments
17.1.10.3.1 Product launches
17.1.10.3.2 Deals
17.1.11 TAKARA BIO INC.
17.1.11.1 Business overview
17.1.11.2 Products/services offered
17.1.11.3 Recent developments
17.1.11.3.1 Product launches
17.1.11.3.2 Deals
17.1.12 BGI GROUP
17.1.12.1 Business overview
17.1.12.2 Products/services offered
17.1.12.3 Recent developments
17.1.12.3.1 Product & service launches and approvals
17.1.12.3.2 Deals
17.1.12.3.3 Other developments
17.1.13 BD
17.1.13.1 Business overview
17.1.13.2 Products/services offered
17.1.13.3 Recent developments
17.1.13.3.1 Product & service launches
17.1.13.3.2 Deals
17.1.14 10X GENOMICS
17.1.14.1 Business overview
17.1.14.2 Products/services offered
17.1.14.3 Recent developments
17.1.14.3.1 Product launches
17.1.15 PROMEGA CORPORATION
17.1.15.1 Business overview
17.1.15.2 Products/services offered
17.1.15.3 Recent developments
17.1.15.3.1 Expansions
17.1.16 LGC LIMITED
17.1.16.1 Business overview
17.1.16.2 Products/services offered
17.1.16.2.1 Deals
17.1.17 WUXI BIOLOGICS
17.1.17.1 Business overview
17.1.17.2 Products/services offered
17.1.18 TECAN TRADING AG
17.1.18.1 Business overview
17.1.18.2 Products/services offered
17.1.18.2.1 Deals
17.1.19 TWIST BIOSCIENCES
17.1.19.1 Business overview
17.1.19.2 Products/services offered
17.1.19.3 Recent developments
17.1.19.3.1 Product launches
17.1.19.3.2 Deals
17.1.20 AZENTA US, INC.
17.1.20.1 Business overview
17.1.20.2 Products & services offered
17.1.20.3 Recent developments
17.1.20.3.1 Deals
17.2 OTHER PLAYERS
17.2.1 MGI TECH CO. LTD.
17.2.2 NOVOGENE CO., LTD.
17.2.3 NEW ENGLAND BIOLABS
17.2.4 GENSCRIPT
17.2.5 PSOMAGEN
17.2.6 ZYMO RESEARCH CORPORATION
17.2.7 HAMILTON COMPANY
17.2.8 NEOGENOMICS LABORATORIES
17.2.9 FULGENT GENETICS
17.2.10 SD BIOSENSOR, INC.
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
